Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM 250

Next Previous
Drug Profile

IM 250

Alternative Names: IM-250

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Molecules
  • Class Amides; Antivirals; Fluorobenzenes; Small molecules; Sulfides; Sulfones; Thiazoles; Toluenes
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Herpes genitalis
  • Phase I Herpes simplex virus infections

Most Recent Events

  • 16 Jun 2025 Phase-I/II clinical trials in Herpes genitalis (PO) prior to June 2025
  • 31 Dec 2024 Chemical structure information added.
  • 28 May 2024 Innovative Molecules completes phase I clinical trials in Herpes simplex virus infections (In volunteers) in Germany (PO) (NCT06435507)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top